Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Copy Number Loss at Chromosome 14q11.2 Correlates With the Proportion of T Cells in Biopsies and Helps Identify T-Cell Neoplasms.
Saglam A, Singh K, Kumar J, Gollapudi S, Mukherjee S, Singh A, Butzmann A, Kaplan L, Andreadis C, Ai WZ, Fakhri B, Rajkovic A, Wen KW, Onodera C, Van Ziffle J, Devine PW, Ohgami RS. Saglam A, et al. Among authors: ai wz. Arch Pathol Lab Med. 2023 Aug 1;147(8):940-948. doi: 10.5858/arpa.2022-0193-OA. Arch Pathol Lab Med. 2023. PMID: 36445717 Free article.
Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy.
Banerjee R, Wang V, Huang CY, Pandita D, Leonard MK, LaRue S, Ahmadi M, Kaplan L, Ai WZ, Fakhri B, Spinner M, Seshadri MR, Pampaloni MH, Andreadis CB. Banerjee R, et al. Among authors: ai wz. Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3349-3353. doi: 10.1007/s00259-023-06296-z. Epub 2023 Jun 10. Eur J Nucl Med Mol Imaging. 2023. PMID: 37300573 Free PMC article.
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
Alderuccio JP, Reis IM, Hamadani M, Nachiappan M, Leslom S, Kahl BS, Ai WZ, Radford J, Solh M, Ardeshna KM, Hess BT, Lunning MA, Zinzani PL, Stathis A, Carlo-Stella C, Lossos IS, Caimi PF, Han S, Yang F, Kuker RA, Moskowitz CH. Alderuccio JP, et al. Among authors: ai wz. Clin Cancer Res. 2024 Jan 5;30(1):139-149. doi: 10.1158/1078-0432.CCR-23-1561. Clin Cancer Res. 2024. PMID: 37855688 Free PMC article.
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C. Caimi PF, et al. Among authors: ai wz. Haematologica. 2024 Apr 1;109(4):1184-1193. doi: 10.3324/haematol.2023.283459. Haematologica. 2024. PMID: 37646659 Free PMC article. Clinical Trial.
Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
Iyer SP, Huen A, Ai WZ, Jagadeesh D, Lechowicz MJ, Okada C, Feldman TA, Ghione P, Alderuccio JP, Champion R, Kim SH, Mohrbacher A, Routhu KV, Barde P, Nair AM, Haverkos BM. Iyer SP, et al. Among authors: ai wz. Haematologica. 2024 Jan 1;109(1):209-219. doi: 10.3324/haematol.2022.281875. Haematologica. 2024. PMID: 37439343 Free PMC article. Clinical Trial.
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.
Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF. Alderuccio JP, et al. Among authors: ai wz. Blood Adv. 2022 Aug 23;6(16):4736-4739. doi: 10.1182/bloodadvances.2022007782. Blood Adv. 2022. PMID: 35790100 Free PMC article. No abstract available.
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns JL, Campbell M, Sundar H. Hoppe RT, et al. Among authors: ai wz. J Natl Compr Canc Netw. 2022 Apr;20(4):322-334. doi: 10.6004/jnccn.2022.0021. J Natl Compr Canc Netw. 2022. PMID: 35390768
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. Horwitz SM, et al. Among authors: ai wz. J Natl Compr Canc Netw. 2022 Mar;20(3):285-308. doi: 10.6004/jnccn.2022.0015. J Natl Compr Canc Netw. 2022. PMID: 35276674
54 results